Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus chemotherapy versus chemotherapy alone for platinum-resistant recurrent or metastatic ovarian, fallopian tube, or primary peritoneal cancer
CTR20220599Phase 3Suspended
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of anlotinib in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Apr 2022; status: suspended.
02
Drugs
anlotinib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on CTR20220599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220599.